Management of patients with statin intolerance

被引:11
|
作者
Fischer, Sabine [1 ]
Julius, Ulrich [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Dresden Carl Gustav Carus, Dept Internal Med 3, Lipidol, Fetscherstr 74, D-01307 Dresden, Germany
关键词
Statins; Statin intolerance; Myopathy; Ezetimibe; Bile acid sequestrants; PCSK9; inhibitors; Lipoprotein apheresis; GLOBAL LIPID GUIDELINES; LIPIDOLOGIST PERSPECTIVE; REDUCING LIPIDS; RISK; THERAPY; RECOMMENDATIONS; PREVENTION; ALIROCUMAB; RATIONALE; SYMPTOMS;
D O I
10.1016/j.atherosclerosissup.2017.05.013
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In recent years statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe. When the symptoms are alleviated and creatine kinase is normalized, re-exposition can be considered. If symptoms recur, treatment with another statin should be attempted - in these cases pravastatin or fluvastatin are recommended, although they are less effective in reducing LDL cholesterol. As a rule, at least 3 statins should be tested. In some patients an intake of atorvastatin or rosuvastatin twice weekly may be tolerated and effective. Alternative drugs for patients who cannot tolerate any of the statins are ezetimibe and/or bile acid sequestrants. If LDL cholesterol targets are not reached, PCSK9 inhibitors may be used. In high-risk patients with multiple cardio-vascular events and sub-optimal LDL cholesterol despite lipid-lowering drug therapy a lipoprotein apheresis should be started. In this context, we present the history of a patient, who also had high lipoprotein(a) levels, for whom lipoprotein apheresis therapy was indicated. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 50 条
  • [1] Management of patients with statin intolerance
    Martirossian, Alexandra Nicole
    Goldberg, Anne Carol
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (03)
  • [2] Mayo Clinic: management of patients with statin intolerance
    Zysek, Victoria
    Spoon, Jocelyn
    Kopecky, Stephen
    CLINICAL LIPIDOLOGY, 2013, 8 (05) : 541 - 549
  • [3] Management of the Patient with Statin Intolerance
    Byron F. Vandenberg
    Jennifer Robinson
    Current Atherosclerosis Reports, 2010, 12 : 48 - 57
  • [4] Management of the Patient with Statin Intolerance
    Vandenberg, Byron F.
    Robinson, Jennifer
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (01) : 48 - 57
  • [5] Diagnosis and Management of Statin Intolerance
    Alonso, Rodrigo
    Cuevas, Ada
    Cafferata, Alberto
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2019, 26 (03) : 207 - 215
  • [6] Statin intolerance management: a systematic review
    Alejandra Meza-Contreras
    Camila Wenczenovicz
    Kim Ruiz-Arellanos
    Elissa A. Kinzelman Vesely
    Renzo Mogollon
    Victor M. Montori
    Endocrine, 2023, 79 : 430 - 436
  • [7] Statin intolerance management: a systematic review
    Meza-Contreras, Alejandra
    Wenczenovicz, Camila
    Ruiz-Arellanos, Kim
    Vesely, Elissa A. Kinzelman
    Mogollon, Renzo
    Montori, Victor M.
    ENDOCRINE, 2023, 79 (03) : 430 - 436
  • [8] HYPERLIPIDAEMIA MANAGEMENT IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) AND STATIN INTOLERANCE
    Hossain, R.
    Rallison, C.
    ATHEROSCLEROSIS, 2018, 275 : E84 - E84
  • [9] SAMSON and the Nocebo Effect: Management of Statin Intolerance
    Amrita Krishnamurthy
    Corey Bradley
    Rebecca Ascunce
    Samuel M. Kim
    Current Cardiology Reports, 2022, 24 : 1101 - 1108